Biocept Performance
| BIOCDelisted Stock | USD 1.45 0.17 13.28% |
The firm shows a Beta (market volatility) of 0.81, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Biocept's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biocept is expected to be smaller as well. Biocept right now shows a risk of 0.0%. Please confirm Biocept maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if Biocept will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biocept has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Biocept is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 28.9 M |
Biocept |
Biocept Relative Risk vs. Return Landscape
If you would invest 145.00 in Biocept on August 30, 2024 and sell it today you would earn a total of 0.00 from holding Biocept or generate 0.0% return on investment over 90 days. Biocept is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Biocept, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biocept Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biocept's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biocept, and traders can use it to determine the average amount a Biocept's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BIOC |
Based on monthly moving average Biocept is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biocept by adding Biocept to a well-diversified portfolio.
Biocept Fundamentals Growth
Biocept Stock prices reflect investors' perceptions of the future prospects and financial health of Biocept, and Biocept fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biocept Stock performance.
| Return On Equity | -1.87 | |||
| Return On Asset | -0.52 | |||
| Operating Margin | (10.38) % | |||
| Current Valuation | 5.92 M | |||
| Shares Outstanding | 2.63 M | |||
| Price To Earning | 5.34 X | |||
| Price To Book | 0.37 X | |||
| Price To Sales | 0.20 X | |||
| Revenue | 25.86 M | |||
| EBITDA | (31.98 M) | |||
| Cash And Equivalents | 27.57 M | |||
| Cash Per Share | 1.63 X | |||
| Total Debt | 12.11 M | |||
| Debt To Equity | 0.33 % | |||
| Book Value Per Share | 0.12 X | |||
| Cash Flow From Operations | (13.29 M) | |||
| Earnings Per Share | (48.17) X | |||
| Total Asset | 30.87 M | |||
| Retained Earnings | (298.44 M) | |||
| Current Asset | 9.64 M | |||
| Current Liabilities | 3.34 M | |||
About Biocept Performance
By analyzing Biocept's fundamental ratios, stakeholders can gain valuable insights into Biocept's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biocept has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biocept has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. Biocept operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 177 people.Things to note about Biocept performance evaluation
Checking the ongoing alerts about Biocept for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biocept help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biocept is not yet fully synchronised with the market data | |
| Biocept may become a speculative penny stock | |
| Biocept has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 25.86 M. Net Loss for the year was (32.09 M) with loss before overhead, payroll, taxes, and interest of (2.58 M). | |
| Biocept currently holds about 27.57 M in cash with (13.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Biocept's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biocept's stock is overvalued or undervalued compared to its peers.
- Examining Biocept's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biocept's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biocept's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biocept's stock. These opinions can provide insight into Biocept's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Biocept Stock
If you are still planning to invest in Biocept check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biocept's history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |